应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
NKTR 内克塔治疗
盘前交易 03-28 06:59:31 EDT
0.8851
-0.0149
-1.66%
最高
0.9272
最低
0.8400
成交量
124.03万
今开
0.8800
昨收
0.9000
日振幅
9.69%
总市值
1.63亿
流通市值
1.44亿
总股本
1.84亿
成交额
107.41万
换手率
0.76%
流通股本
1.63亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
内克塔治疗盘中异动 大幅跳水5.44%
自选股智能写手 · 03-27 22:06
内克塔治疗盘中异动 大幅跳水5.44%
内克塔治疗盘中异动 早盘股价大涨5.79%报0.899美元
自选股智能写手 · 03-19
内克塔治疗盘中异动 早盘股价大涨5.79%报0.899美元
内克塔治疗盘中异动 临近午盘股价大跌5.06%报0.845美元
自选股智能写手 · 03-13
内克塔治疗盘中异动 临近午盘股价大跌5.06%报0.845美元
内克塔治疗盘中异动 下午盘股价大涨5.34%
自选股智能写手 · 03-13
内克塔治疗盘中异动 下午盘股价大涨5.34%
内克塔治疗盘中异动 早盘股价大跌5.95%报0.855美元
自选股智能写手 · 03-11
内克塔治疗盘中异动 早盘股价大跌5.95%报0.855美元
内克塔治疗盘中异动 下午盘急速下跌5.56%报0.903美元
自选股智能写手 · 03-09
内克塔治疗盘中异动 下午盘急速下跌5.56%报0.903美元
内克塔治疗2023财年实现净利润-2.76亿美元,同比增加25.00%
自选股智能写手 · 03-09
内克塔治疗2023财年实现净利润-2.76亿美元,同比增加25.00%
内克塔治疗盘中异动 快速上涨5.48%
自选股智能写手 · 03-07
内克塔治疗盘中异动 快速上涨5.48%
内克塔治疗盘中异动 股价大涨5.19%报0.930美元
自选股智能写手 · 03-06
内克塔治疗盘中异动 股价大涨5.19%报0.930美元
美国研究综述-Arrivent 生物制药公司、弗格森公司、目标公司
Reuters · 03-06
美国研究综述-Arrivent 生物制药公司、弗格森公司、目标公司
内克塔治疗盘中异动 大幅下挫5.54%
自选股智能写手 · 03-05
内克塔治疗盘中异动 大幅下挫5.54%
Nektar Therapeutics 预计每股亏损 21 美分 - 财报前瞻
Reuters · 03-02
Nektar Therapeutics 预计每股亏损 21 美分 - 财报前瞻
内克塔治疗盘中异动 快速拉升5.58%报0.750美元
自选股智能写手 · 03-01
内克塔治疗盘中异动 快速拉升5.58%报0.750美元
内克塔治疗盘中异动 快速跳水5.33%报0.710美元
自选股智能写手 · 02-29
内克塔治疗盘中异动 快速跳水5.33%报0.710美元
内克塔治疗盘中异动 大幅拉升5.30%报0.719美元
自选股智能写手 · 02-27
内克塔治疗盘中异动 大幅拉升5.30%报0.719美元
内克塔治疗盘中异动 急速拉升5.13%报0.695美元
自选股智能写手 · 02-24
内克塔治疗盘中异动 急速拉升5.13%报0.695美元
内克塔治疗盘中异动 早盘大幅上涨5.12%
自选股智能写手 · 02-22
内克塔治疗盘中异动 早盘大幅上涨5.12%
加载更多
公司概况
公司名称:
内克塔治疗
所属市场:
NASDAQ
上市日期:
--
主营业务:
Nektar Therapeutics于1990年在加州成立,并于1998年重新在特拉华州注册。这是临床阶段生物制药公司,其利用PEG修饰和先进的聚合物共轭技术平台开发一个管道的候选药物。这些平台是为了认识其作用机制确保新分子实体的发展。当前专用管道包括跨多个治疗领域包括肿瘤、疼痛、抗感染和免疫领域候选药物。研究和开发活动涉及两种小分子和生物药物的候选。公司通过使用专有先进聚合物共轭技术来修改药效基因创建新的分子实体的化学结构,从而来创建创新候选药物。司收入来源于与伙伴合作协议,它可以接收合同研究支付、根据临床进展和监管进展或净销售额获得里程碑付款、版税或生产收入。
发行价格:
--
{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"内克塔治疗","latestPrice":0.8851,"timestamp":1711569600000,"preClose":0.9,"halted":0,"volume":1240253,"delay":0,"floatShares":163107027,"shares":183617817,"eps":-1.452918,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.0149,"latestTime":"03-28 06:59:31 EDT","open":0.88,"high":0.9272,"low":0.84,"amount":1074092.3367804,"amplitude":0.096889,"askPrice":0.9767,"askSize":100,"bidPrice":0.8,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.452918,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1711632600000},"adr":0,"adjPreClose":0.8851,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":0.8503,"preClose":0.8851,"latestTime":"19:51 EDT","volume":3089,"amount":2680.4248,"timestamp":1711583492377},"volumeRatio":1.1478710353783477},"requestUrl":"/m/hq/s/NKTR","defaultTab":"news","newsList":[{"id":"2422918097","title":"内克塔治疗盘中异动 大幅跳水5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422918097","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422918097?lang=zh_cn&edition=full","pubTime":"2024-03-27 22:06","pubTimestamp":1711548388,"startTime":"0","endTime":"0","summary":"北京时间2024年03月27日22时06分,内克塔治疗股票出现异动,股价急速跳水5.44%。截至发稿,该股报0.851美元/股,成交量13.6782万股,换手率0.07%,振幅4.44%。机构评级方面,在所有4家参与评级的机构中,100%的券商给予持有建议,无券商给予买入、卖出建议。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.37%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272206287a4f88f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272206287a4f88f0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420517273","title":"内克塔治疗盘中异动 早盘股价大涨5.79%报0.899美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420517273","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420517273?lang=zh_cn&edition=full","pubTime":"2024-03-19 22:28","pubTimestamp":1710858506,"startTime":"0","endTime":"0","summary":"北京时间2024年03月19日22时28分,内克塔治疗股票出现异动,股价快速上涨5.79%。截至发稿,该股报0.899美元/股,成交量18.0262万股,换手率0.10%,振幅6.81%。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.04%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。该公司拥有肿瘤学、免疫学和病毒学研究药物的全资研发管线,以及一系列获批的合作药物。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240319222827791b7b14&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240319222827791b7b14&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419033639","title":"内克塔治疗盘中异动 临近午盘股价大跌5.06%报0.845美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2419033639","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419033639?lang=zh_cn&edition=full","pubTime":"2024-03-13 23:46","pubTimestamp":1710344767,"startTime":"0","endTime":"0","summary":"北京时间2024年03月13日23时46分,内克塔治疗股票出现波动,股价大幅跳水5.06%。截至发稿,该股报0.845美元/股,成交量60.2592万股,换手率0.33%,振幅7.53%。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.43%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。公司拥有肿瘤学、免疫学、病毒学等临床试验药物的全资研发渠道,并拥有一批获批准的合作药物。在病毒学领域,该公司相信选择性免疫调节剂可以用于治疗人类的病毒感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240313234607791a1fcf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240313234607791a1fcf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419661625","title":"内克塔治疗盘中异动 下午盘股价大涨5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2419661625","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419661625?lang=zh_cn&edition=full","pubTime":"2024-03-13 02:09","pubTimestamp":1710266998,"startTime":"0","endTime":"0","summary":"北京时间2024年03月13日02时09分,内克塔治疗股票出现波动,股价快速拉升5.34%。截至发稿,该股报0.876美元/股,成交量93.773万股,换手率0.51%,振幅5.01%。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.91%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。公司拥有肿瘤学、免疫学、病毒学等临床试验药物的全资研发渠道,并拥有一批获批准的合作药物。在病毒学领域,该公司相信选择性免疫调节剂可以用于治疗人类的病毒感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403130209587919c664&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403130209587919c664&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2418656853","title":"内克塔治疗盘中异动 早盘股价大跌5.95%报0.855美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2418656853","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2418656853?lang=zh_cn&edition=full","pubTime":"2024-03-11 22:18","pubTimestamp":1710166682,"startTime":"0","endTime":"0","summary":"北京时间2024年03月11日22时18分,内克塔治疗股票出现波动,股价大幅跳水5.95%。截至发稿,该股报0.855美元/股,成交量9.5766万股,换手率0.05%,振幅4.29%。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.00%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。公司拥有肿瘤学、免疫学、病毒学等临床试验药物的全资研发渠道,并拥有一批获批准的合作药物。在病毒学领域,该公司相信选择性免疫调节剂可以用于治疗人类的病毒感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031122180287e77caa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031122180287e77caa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2418709311","title":"内克塔治疗盘中异动 下午盘急速下跌5.56%报0.903美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2418709311","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2418709311?lang=zh_cn&edition=full","pubTime":"2024-03-09 02:03","pubTimestamp":1709920982,"startTime":"0","endTime":"0","summary":"北京时间2024年03月09日02时03分,内克塔治疗股票出现异动,股价急速下跌5.56%。截至发稿,该股报0.903美元/股,成交量59.9892万股,换手率0.33%,振幅9.92%。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.73%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。公司拥有肿瘤学、免疫学、病毒学等临床试验药物的全资研发渠道,并拥有一批获批准的合作药物。在病毒学领域,该公司相信选择性免疫调节剂可以用于治疗人类的病毒感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403090203027918ade6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403090203027918ade6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2418061669","title":"内克塔治疗2023财年实现净利润-2.76亿美元,同比增加25.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2418061669","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2418061669?lang=zh_cn&edition=full","pubTime":"2024-03-09 00:22","pubTimestamp":1709914960,"startTime":"0","endTime":"0","summary":"12月31日,内克塔治疗公布财报,公告显示公司2023财年净利润为-2.76亿美元,同比增加25.00%;其中营业收入为90.12百万美元,同比减少2.11%,每股基本收益为-1.45美元。从资产负债表来看,内克塔治疗总负债2.67亿美元,其中短期债务19.26百万美元,资产负债比为1.50,流动比率为0.07。机构评级:截至2023年12月31日,当前有2家机构对内克塔治疗目标价做出预测,其中目标均价为3.00美元,其中最低目标价为1.00美元,最高目标价为5.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403090022438b18f6be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403090022438b18f6be&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417076073","title":"内克塔治疗盘中异动 快速上涨5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417076073","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417076073?lang=zh_cn&edition=full","pubTime":"2024-03-07 22:43","pubTimestamp":1709822586,"startTime":"0","endTime":"0","summary":"北京时间2024年03月07日22时43分,内克塔治疗股票出现波动,股价急速上涨5.48%。截至发稿,该股报0.960美元/股,成交量13.6926万股,换手率0.07%,振幅7.68%。内克塔治疗股票所在的生物技术行业中,整体涨幅为2.45%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。公司拥有肿瘤学、免疫学、病毒学等临床试验药物的全资研发渠道,并拥有一批获批准的合作药物。在病毒学领域,该公司相信选择性免疫调节剂可以用于治疗人类的病毒感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030722430679184724&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030722430679184724&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417971052","title":"内克塔治疗盘中异动 股价大涨5.19%报0.930美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2417971052","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417971052?lang=zh_cn&edition=full","pubTime":"2024-03-06 22:33","pubTimestamp":1709735630,"startTime":"0","endTime":"0","summary":"北京时间2024年03月06日22时33分,内克塔治疗股票出现波动,股价大幅上涨5.19%。截至发稿,该股报0.930美元/股,成交量5.6431万股,换手率0.03%,振幅4.52%。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.14%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。公司拥有肿瘤学、免疫学、病毒学等临床试验药物的全资研发渠道,并拥有一批获批准的合作药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030622335087e7681f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030622335087e7681f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417239460","title":"美国研究综述-Arrivent 生物制药公司、弗格森公司、目标公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2417239460","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417239460?lang=zh_cn&edition=full","pubTime":"2024-03-06 14:48","pubTimestamp":1709707680,"startTime":"0","endTime":"0","summary":" 路透社3月6日 - 华尔街证券分析师周三调整了对 Arrivent Biopharma、Ferguson 和 Target 等几家美国上市公司的评级和目标价。要闻 * Arrivent Biopharma Inc :杰富瑞给予买入评级 * 弗格森 :杰富瑞将目标价从 222 美元上调至 244 美元 * Target Corp :汇丰银行将其评级从 \"持有 \"上调至 \"买入\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417544844","title":"内克塔治疗盘中异动 大幅下挫5.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417544844","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417544844?lang=zh_cn&edition=full","pubTime":"2024-03-05 23:06","pubTimestamp":1709651161,"startTime":"0","endTime":"0","summary":"北京时间2024年03月05日23时06分,内克塔治疗股票出现波动,股价快速下挫5.54%。截至发稿,该股报0.850美元/股,成交量127.686万股,换手率0.67%,振幅7.64%。内克塔治疗股票所在的生物技术行业中,整体跌幅为1.10%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。公司拥有肿瘤学、免疫学、病毒学等临床试验药物的全资研发渠道,并拥有一批获批准的合作药物。在病毒学领域,该公司相信选择性免疫调节剂可以用于治疗人类的病毒感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030523060187e761d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030523060187e761d2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416608790","title":"Nektar Therapeutics 预计每股亏损 21 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2416608790","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2416608790?lang=zh_cn&edition=full","pubTime":"2024-03-02 06:39","pubTimestamp":1709332754,"startTime":"0","endTime":"0","summary":" * Nektar Therapeutics 将于3月4日公布截至2023年12月31日的财报,预计季度收入将出现下降。* 根据LSEG的数据,5位分析师的平均预期显示,这家总部位于加利福尼亚州旧金山的公司的营收预计将从去年同期的2202万美元下降18.0%,至1805.5万美元。) * LSEG 分析师对 Nektar Therapeutics 的平均预期是每股亏损 21 美分。* 华尔街对 Nektar Therapeutics 的 12 个月目标价中位数为 1.75 美元,高于其 0.78 美元的最新收盘价。3月1日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2416640373","title":"内克塔治疗盘中异动 快速拉升5.58%报0.750美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2416640373","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416640373?lang=zh_cn&edition=full","pubTime":"2024-03-01 23:51","pubTimestamp":1709308277,"startTime":"0","endTime":"0","summary":"北京时间2024年03月01日23时51分,内克塔治疗股票出现异动,股价快速拉升5.58%。截至发稿,该股报0.750美元/股,成交量24.0133万股,换手率0.13%,振幅4.20%。内克塔治疗股票所在的生物技术行业中,整体涨幅为2.37%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。公司拥有肿瘤学、免疫学、病毒学等临床试验药物的全资研发渠道,并拥有一批获批准的合作药物。在病毒学领域,该公司相信选择性免疫调节剂可以用于治疗人类的病毒感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403012351187a489989&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403012351187a489989&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2415304018","title":"内克塔治疗盘中异动 快速跳水5.33%报0.710美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2415304018","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2415304018?lang=zh_cn&edition=full","pubTime":"2024-02-29 03:52","pubTimestamp":1709149962,"startTime":"0","endTime":"0","summary":"北京时间2024年02月29日03时52分,内克塔治疗股票出现波动,股价快速下挫5.33%。截至发稿,该股报0.710美元/股,成交量114.936万股,换手率0.60%,振幅9.33%。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.77%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。公司拥有肿瘤学、免疫学、病毒学等临床试验药物的全资研发渠道,并拥有一批获批准的合作药物。在病毒学领域,该公司相信选择性免疫调节剂可以用于治疗人类的病毒感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240229035243791598bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240229035243791598bf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2414450858","title":"内克塔治疗盘中异动 大幅拉升5.30%报0.719美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2414450858","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2414450858?lang=zh_cn&edition=full","pubTime":"2024-02-27 01:45","pubTimestamp":1708969501,"startTime":"0","endTime":"0","summary":"北京时间2024年02月27日01时45分,内克塔治疗股票出现异动,股价急速拉升5.30%。截至发稿,该股报0.719美元/股,成交量47.8866万股,换手率0.25%,振幅6.15%。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.20%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。公司拥有肿瘤学、免疫学、病毒学等临床试验药物的全资研发渠道,并拥有一批获批准的合作药物。在病毒学领域,该公司相信选择性免疫调节剂可以用于治疗人类的病毒感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022701450187e73328&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022701450187e73328&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413903387","title":"内克塔治疗盘中异动 急速拉升5.13%报0.695美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2413903387","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413903387?lang=zh_cn&edition=full","pubTime":"2024-02-24 02:33","pubTimestamp":1708713190,"startTime":"0","endTime":"0","summary":"北京时间2024年02月24日02时33分,内克塔治疗股票出现波动,股价急速上涨5.13%。截至发稿,该股报0.695美元/股,成交量48.6013万股,换手率0.25%,振幅9.02%。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.68%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。公司拥有肿瘤学、免疫学、病毒学等临床试验药物的全资研发渠道,并拥有一批获批准的合作药物。在病毒学领域,该公司相信选择性免疫调节剂可以用于治疗人类的病毒感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240224023310861d7f6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240224023310861d7f6b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413357217","title":"内克塔治疗盘中异动 早盘大幅上涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2413357217","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413357217?lang=zh_cn&edition=full","pubTime":"2024-02-22 22:37","pubTimestamp":1708612646,"startTime":"0","endTime":"0","summary":"北京时间2024年02月22日22时37分,内克塔治疗股票出现异动,股价急速拉升5.12%。截至发稿,该股报0.725美元/股,成交量6901股,换手率0.00%,振幅1.45%。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.96%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。公司拥有肿瘤学、免疫学、病毒学等临床试验药物的全资研发渠道,并拥有一批获批准的合作药物。在病毒学领域,该公司相信选择性免疫调节剂可以用于治疗人类的病毒感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240222223726861d77ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240222223726861d77ed&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":-0.0166},{"period":"1month","weight":0.321},{"period":"3month","weight":0.6034},{"period":"6month","weight":0.4861},{"period":"1year","weight":0.2459},{"period":"ytd","weight":0.5665}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.034},{"period":"3month","weight":0.0975},{"period":"6month","weight":0.2238},{"period":"1year","weight":0.3225},{"period":"ytd","weight":0.1007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nektar Therapeutics于1990年在加州成立,并于1998年重新在特拉华州注册。这是临床阶段生物制药公司,其利用PEG修饰和先进的聚合物共轭技术平台开发一个管道的候选药物。这些平台是为了认识其作用机制确保新分子实体的发展。当前专用管道包括跨多个治疗领域包括肿瘤、疼痛、抗感染和免疫领域候选药物。研究和开发活动涉及两种小分子和生物药物的候选。公司通过使用专有先进聚合物共轭技术来修改药效基因创建新的分子实体的化学结构,从而来创建创新候选药物。司收入来源于与伙伴合作协议,它可以接收合同研究支付、根据临床进展和监管进展或净销售额获得里程碑付款、版税或生产收入。","yearOnYearQuotes":[{"month":1,"riseRate":0.566667,"avgChangeRate":0.047978},{"month":2,"riseRate":0.5,"avgChangeRate":0.00268},{"month":3,"riseRate":0.4,"avgChangeRate":0.001924},{"month":4,"riseRate":0.413793,"avgChangeRate":-0.012886},{"month":5,"riseRate":0.37931,"avgChangeRate":0.010886},{"month":6,"riseRate":0.4,"avgChangeRate":-0.018551},{"month":7,"riseRate":0.433333,"avgChangeRate":-0.018183},{"month":8,"riseRate":0.466667,"avgChangeRate":0.036795},{"month":9,"riseRate":0.466667,"avgChangeRate":0.014605},{"month":10,"riseRate":0.366667,"avgChangeRate":-0.026724},{"month":11,"riseRate":0.7,"avgChangeRate":0.094193},{"month":12,"riseRate":0.633333,"avgChangeRate":0.03444}],"exchange":"NASDAQ","name":"内克塔治疗","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"内克塔治疗,NKTR,内克塔治疗股票,内克塔治疗股票老虎,内克塔治疗股票老虎国际,内克塔治疗行情,内克塔治疗股票行情,内克塔治疗股价,内克塔治疗股市,内克塔治疗股票价格,内克塔治疗股票交易,内克塔治疗股票购买,内克塔治疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}